Cord Blood America, Inc. (CBAI.OB) reports that Buyins.net recently released a research report reflecting trading data on the Company. From June 2005 to April 2007 approximately 129.2 million total aggregate shares of CBAI were traded for a total dollar value of nearly $36.6 million.
The total aggregate number of shares shorted in this time period was approximately 9.9 million shares. The CBAI SqueezeTrigger price of $0.28 is the volume weighted average short price of all short selling in CBAI. The first of several short squeezes is expected to begin when shares of CBAI close above $.09 per share, where over 173,000 shares have been shorted.
Cord Blood America, Inc. is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders.
Let us hear your thoughts below: